Prostate-Specific Antigen Doubling Time as a Surrogate Marker for Evaluation of Oncologic Drugs to Treat Prostate Cancer
Open Access
- 1 June 2004
- journal article
- review article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 10 (11) , 3927-3933
Abstract
No abstract availableKeywords
This publication has 45 references indexed in Scilit:
- Cancer Statistics, 2004CA: A Cancer Journal for Clinicians, 2004
- The Addition of Interleukin-6 Soluble Receptor and Transforming Growth Factor Beta1 Improves a Preoperative Nomogram for Predicting Biochemical Progression in Patients With Clinically Localized Prostate CancerJournal of Clinical Oncology, 2003
- Endothelin receptor antagonists in the treatment of prostate cancerSeminars in Oncology, 2003
- Elevated serum progastrin‐releasing peptide (31–98) level is a predictor of short response duration after hormonal therapy in metastatic prostate cancerThe Prostate, 2003
- Imatinib alone and in combination for chronic myeloid leukemiaSeminars in Hematology, 2003
- Determinants of Prostate Cancer–Specific Survival After Radiation Therapy for Patients With Clinically Localized Prostate CancerJournal of Clinical Oncology, 2002
- Prognostic Significance of The Nadir Prostate Specific Antigen Level After Hormone Therapy for Prostate CancerJournal of Urology, 2002
- New Guidelines to Evaluate the Response to Treatment in Solid TumorsJNCI: Journal of the National Cancer Institute, 2000
- Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update1997
- Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate diseaseJAMA, 1992